- Previous Close
0.0120 - Open
0.0120 - Bid 0.0130 x --
- Ask 0.0140 x --
- Day's Range
0.0120 - 0.0130 - 52 Week Range
0.0120 - 0.0260 - Volume
142,873 - Avg. Volume
623,641 - Market Cap (intraday)
22.955M - Beta (5Y Monthly) 1.72
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Clever Culture Systems Limited engages in the research, development, and commercialization of technology solutions for medical industry in Australia, the United States, Sweden, the United Kingdom, and Germany. The company offers Automated Plate Assessment System (APAS) Independence, a solution that automates the imaging, analysis, and interpretation of microbiology culture plates primarily for microbiology laboratories and pharmaceutical manufacturing sector; APAS Analysis Modules, a software algorithm that enables the screening of microbiology culture plates collected during environmental monitoring; and APAS PharmaQC, an artificial intelligence for culture plate reading. It also develops APAS intelligent imaging technology for various applications, which includes wound treatment, histopathology, and antimicrobial susceptibility testing. The company was formerly known as LBT Innovations Limited and changed its name to Clever Culture Systems Limited in November 2024. Clever Culture Systems Limited was incorporated in 2004 and is headquartered in Adelaide, Australia.
www.cleverculturesystems.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: CC5.AX
View MorePerformance Overview: CC5.AX
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CC5.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CC5.AX
View MoreValuation Measures
Market Cap
22.96M
Enterprise Value
22.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.71
Price/Book (mrq)
4.81
Enterprise Value/Revenue
18.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-23.72%
Return on Assets (ttm)
-19.86%
Return on Equity (ttm)
-21.82%
Revenue (ttm)
3.37M
Net Income Avi to Common (ttm)
-799k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.7M
Total Debt/Equity (mrq)
51.25%
Levered Free Cash Flow (ttm)
-3.51M